Interaction entre Eszopiclone et Gabapentine
Eszopiclone et Gabapentine : les deux notices de prescription signalent cette association dans les termes les plus forts, tels qu'une contre-indication, une mise en garde encadrée ou une consigne de l'éviter.
Ne pas associer sans l'avis d'un prescripteur. Les termes de la notice cités ci-dessous sont les plus forts qu'emploie la FDA.
Ce que disent les notices FDA
D'après la notice Eszopiclone (Lunesta) · version du 2025-01-08
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended.
Risk increases with dose and use with other CNS depressants and alcohol.
Post-marketing reports have shown that complex sleep behaviors may occur with LUNESTA alone at recommended dosages, with or without the concomitant use of alcohol or other CNS depressants [see Drug Interactions ( 7.1 )] .
Additive effects occur with concomitant use of other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol), including daytime use.
…psychomotor impairment is increased if LUNESTA is taken with less than a full night of sleep remaining (7- to 8 hours); if higher than the recommended dose is taken; if coadministered with other CNS depressants; or coadministered with other drugs that increase the blood levels of eszopiclone [see Dosage and Administration ( 2.3 ) and Clinical Studies ( 14.3 )].
D'après la notice Gabapentine (Neurontin) · version du 2026-05-12
• Respiratory Depression: May occur with NEURONTIN when used with concomitant central nervous system (CNS) depressants, including opioids, or in the setting of underlying respiratory impairment.
Respiratory Depression There is evidence from case reports, human studies, and animal studies associating gabapentin with serious, life-threatening, or fatal respiratory depression when coadministered with CNS depressants, including opioids, or in the setting of underlying respiratory impairment.
The management of respiratory depression may include close observation, supportive measures, and reduction or withdrawal of CNS depressants (including NEURONTIN).
When the decision is made to co-prescribe NEURONTIN with another CNS depressant, particularly an opioid, or to prescribe NEURONTIN to patients with underlying respiratory impairment, monitor patients for symptoms of respiratory depression and sedation, and consider initiating NEURONTIN at a low dose.
Patients should be carefully observed for signs of central nervous system (CNS) depression, such as somnolence and sedation, when NEURONTIN is used with other drugs with sedative properties because of potential synergy.
Vous prenez autre chose que ces deux-là ? Les interactions se cumulent. Vérifiez toute votre liste en une fois ; elle reste dans votre navigateur.
Ouvrir dans le vérificateurCeci n'est pas un avis médical. Interaction Checker cite le texte des notices FDA et des fiches d'information du NIH. L'importance d'une interaction dans votre cas dépend des doses, des horaires de prise, de la fonction rénale et hépatique et d'autres problèmes de santé. Vérifiez auprès d'un pharmacien ou d'un prescripteur.